BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21788964)

  • 1. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
    Grimminger PP; Shi M; Barrett C; Lebwohl D; Danenberg KD; Brabender J; Vigen CL; Danenberg PV; Winder T; Lenz HJ
    Pharmacogenomics J; 2012 Oct; 12(5):404-11. PubMed ID: 21788964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
    Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H; Onouchi T; Yakabi K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2220-3. PubMed ID: 22202336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
    Ishibashi K; Okada N; Ishiguro T; Kuwabara K; Ohsawa T; Yokoyama M; Kumamoto K; Haga N; Mori T; Yamada H; Miura I; Tamaru J; Itoyama S; Ishida H
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2532-5. PubMed ID: 21224630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
    Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
    Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
    Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
    Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
    PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
    Cascinu S; Aschele C; Barni S; Debernardis D; Baldo C; Tunesi G; Catalano V; Staccioli MP; Brenna A; Muretto P; Catalano G
    Clin Cancer Res; 1999 Aug; 5(8):1996-9. PubMed ID: 10473077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
    Kuwabara K; Kumamoto K; Ishibashi K; Okada N; Ishiguro T; Ohsawa T; Haga N; Miura I; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2224-7. PubMed ID: 22202337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
    Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
    Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
    Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.
    Douillard JY; Siena S; Peeters M; Koukakis R; Terwey JH; Tabernero J
    Eur J Cancer; 2015 Jul; 51(10):1231-42. PubMed ID: 25956209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
    Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.